Even with maximally tolerated statin treatment regimens, atherosclerotic cardiovascular disease (ASCVD) patients with concomitant cardiovascular risk factors may be at risk of major adverse cardiovascular events (MACE).1 Join Prof. Shaun Goodman and leading Australian clinicians Prof. Leon Simons, A/Prof. Karam Kostner and Prof. David Hare in a series of three online presentations and open discussion ...
Sanofi Webinar Series with Prof Shaun Goodman: Reducing residual ASCVD risk with LDL-C lowering therapies in real-world clinical practice
26 Jul 2021
Sponsored by sanofi-aventis australia pty ltd